Literature DB >> 12759323

Race, quality of care, and outcomes of elderly patients hospitalized with heart failure.

Saif S Rathore1, JoAnne M Foody, Yongfei Wang, Grace L Smith, Jeph Herrin, Frederick A Masoudi, Pamela Wolfe, Edward P Havranek, Diana L Ordin, Harlan M Krumholz.   

Abstract

CONTEXT: Black patients hospitalized with heart failure reportedly receive poorer quality of care and have worse outcomes than white patients. Because previous studies have been based on selected patient populations treated more than a decade ago, it is unclear if racial differences in quality of care and outcomes currently exist in the United States.
OBJECTIVE: To evaluate differences in quality of care and patient outcomes between black and white Medicare beneficiaries hospitalized with heart failure.
DESIGN: Retrospective analysis of medical record data systematically collected for the National Heart Failure Project. SETTING AND PATIENTS: Nationwide US sample of 29 732 fee-for-service Medicare beneficiaries hospitalized with heart failure in 1998 and 1999. MAIN OUTCOME MEASURES: Prescription of angiotensin-converting enzyme (ACE) inhibitors, measurement of left ventricular ejection fraction (LVEF), readmission within 1 year of discharge, and mortality within 30 days and 1 year of admission.
RESULTS: Black patients and white patients had similar crude rates of LVEF assessment (67.8% black vs 66.6% white; P =.29). Among patients classified as ideal for ACE inhibitor use, black patients had higher crude rates of ACE inhibitor use than white patients (81.0% vs 73.8% white; P<.001) but had similar rates of ACE inhibitor or angiotensin receptor blocker (ARB) use (85.7% black vs 82.5% white; P =.08). After multivariable adjustment, black patients had comparable rates of LVEF assessment (risk ratio [RR], 0.99; 95% confidence interval [CI], 0.95-1.03). Black patients remained more likely to be prescribed ACE inhibitors (RR, 1.22; 95% CI, 1.14-1.28) than were white patients in an adjusted analysis, but there were no significant racial differences in the prescription of ACE inhibitors or ARBs (black vs white, RR, 1.03; 95% CI, 0.97-1.07). Black patients had higher rates of readmission within 1 year of discharge (68.2% vs 63.0%; P<.001) but had lower crude 30-day (6.3% vs 10.7%; P<.001) and 1-year (31.5% vs 40.1%; P<.001) mortality rates than white patients. After multivariable adjustment, black patients had a slightly higher rate of readmission than white patients (RR, 1.09; 95% CI, 1.06-1.13) but remained at lower risk of 30-day mortality (RR, 0.78; 95% CI, 0.68-0.91) and 1-year mortality (RR, 0.93; 95% CI, 0.88-0.98).
CONCLUSIONS: Black Medicare patients hospitalized with heart failure received comparable quality of care and had slightly higher rates of readmission but had lower mortality rates up to 1 year after hospitalization than did white patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759323     DOI: 10.1001/jama.289.19.2517

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  70 in total

Review 1.  Ethnic disparities in patients with systemic lupus erythematosus.

Authors:  América G Uribe; Graciela S Alarcón
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 2.  Heart failure in women.

Authors:  J Julia Shin; Eman Hamad; Sandhya Murthy; Ileana L Piña
Journal:  Clin Cardiol       Date:  2012-03       Impact factor: 2.882

3.  Is patient-perceived severity of a geriatric condition related to better quality of care?

Authors:  Lillian C Min; David B Reuben; Emmett Keeler; David A Ganz; Constance H Fung; Paul Shekelle; Carol P Roth; Neil S Wenger
Journal:  Med Care       Date:  2011-01       Impact factor: 2.983

4.  Racial and Ethnic Differences in Heart Failure Readmissions and Mortality in a Large Municipal Healthcare System.

Authors:  Matthew S Durstenfeld; Olugbenga Ogedegbe; Stuart D Katz; Hannah Park; Saul Blecker
Journal:  JACC Heart Fail       Date:  2016-07-06       Impact factor: 12.035

5.  Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria.

Authors:  Wayne D Rosamond; Patricia P Chang; Chris Baggett; Anna Johnson; Alain G Bertoni; Eyal Shahar; Anita Deswal; Gerardo Heiss; Lloyd E Chambless
Journal:  Circ Heart Fail       Date:  2012-01-23       Impact factor: 8.790

6.  Explaining black-white differences in receipt of recommended colon cancer treatment.

Authors:  Laura-Mae Baldwin; Sharon A Dobie; Kevin Billingsley; Yong Cai; George E Wright; Jason A Dominitz; William Barlow; Joan L Warren; Stephen H Taplin
Journal:  J Natl Cancer Inst       Date:  2005-08-17       Impact factor: 13.506

7.  Glutamine Regulates Cardiac Progenitor Cell Metabolism and Proliferation.

Authors:  Joshua K Salabei; Pawel K Lorkiewicz; Candice R Holden; Qianhong Li; Kyung U Hong; Roberto Bolli; Aruni Bhatnagar; Bradford G Hill
Journal:  Stem Cells       Date:  2015-05-26       Impact factor: 6.277

8.  Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis.

Authors:  Hossein Bahrami; Richard Kronmal; David A Bluemke; Jean Olson; Steven Shea; Kiang Liu; Gregory L Burke; João A C Lima
Journal:  Arch Intern Med       Date:  2008-10-27

9.  Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST).

Authors:  Linda G Jones; Mo-Kyung Sin; Fadi G Hage; Raya E Kheirbek; Charity J Morgan; Michael R Zile; Wen-Chih Wu; Prakash Deedwania; Gregg C Fonarow; Wilbert S Aronow; Sumanth D Prabhu; Ross D Fletcher; Ali Ahmed; Richard M Allman
Journal:  Circ Heart Fail       Date:  2014-12-05       Impact factor: 8.790

10.  Hospital-Readmission Risk - Isolating Hospital Effects from Patient Effects.

Authors:  Harlan M Krumholz; Kun Wang; Zhenqiu Lin; Kumar Dharmarajan; Leora I Horwitz; Joseph S Ross; Elizabeth E Drye; Susannah M Bernheim; Sharon-Lise T Normand
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.